Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

Author's Avatar
Jan 24, 2022

Spruce+Biosciences%2C+Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).